Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics

Patent metadata

Field	Value
Publication number	US-10098934-B2
Application number	US-201313845420-A
Country	US
Kind code	B2
Filing date	Mar 18, 2013
Priority date	Sep 4, 2007
Publication date	Oct 16, 2018
Grant date	Oct 16, 2018

Abstract

This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants awhich are suitable targets for immunotherapy, cancer therapy, and drug development.

First claim

What is claimed is:

1. A monoclonal or polyclonal antibody or an antigen binding fragment thereof comprising an antigen binding site that binds specifically to an isolated polypeptide of SEQ ID NO:48.

2. The antibody or antigen binding fragment according to claim 1 , comprising an antigen binding site that binds specifically to an isolated polypeptide of SEQ ID NO:299.

3. The antibody or antigen binding fragment according to claim 1 , wherein the antibody is a fully human antibody, chimeric antibody, humanized or primatized antibody; bispecific antibody, Fab, Fab′, F(ab′)2, F(ab′), F(ab), Fv or scFv fragment and minimal recognition unit.

4. The antibody or antigen binding fragment according to claim 1 , wherein the antibody is coupled to a moiety selected from a drug, a radionuclide, a fluorophore, an enzyme, a toxin, a therapeutic agent, a chemotherapeutic agent, or a detectable marker; and wherein the detectable marker is a radioisotope, a metal chelator, an enzyme, a fluorescent compound, a bioluminescent compound or a chemiluminescent compound.

5. The antibody of claim 4 , that elicits apoptosis or lysis of cells that express a polypeptide of SEQ ID NO:48.

6. A pharmaceutical composition comprising the antibody or antigen binding fragment according to claim 1 and further comprising a pharmaceutically acceptable diluent or carrier.

7. A method for detecting a polypeptide, comprising detecting expression of the polypeptide of SEQ ID NO:48, wherein said detecting is performed in vivo or in vitro in an immunoassay with an antibody which specifically interacts with the polypeptide of SEQ ID NO:48.

8. An assay for detecting the presence of a polypeptide of SEQ ID NO:147, SEQ ID NO:299 or SEQ ID NO:48, in a biological sample comprising contacting the sample with an antibody according to claim 1 , and detecting the binding of the antibody to the polypeptide of SEQ ID NO:147, SEQ ID NO:299 or SEQ ID NO:48 in the sample.

9. The antibody or antigen binding fragment according to claim 1 , comprising an antigen binding site that binds specifically to an isolated polypeptide of SEQ ID NO:147.

Assignees

• Compugen Ltd
• Compugen Ltd

Inventors

• Levine Zurit
• Toporik Amir
• Novik Amit
• Cohen-Dayag Anat
• Rosenberg Avi
• Koifman Cynthia
• Landesman-Milo Dalit
• Montia Eve
• Rotman Galit
• Dassa Liat
• Bubis Marina
• Beiman Merav
• Levy Ofer
• Nemzer Sergey
• Walach Shira
• Greenwald Shirley Sameach-
• Pergam Tania
• Kinar Yaron

Classifications

• A61P35/02

  specific for leukemia · CPC title

• A61P7/06

  Antianaemics · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/04

  specific for metastasis · CPC title

• A61P5/14

  of the thyroid hormones, e.g. T3, T4 · CPC title